Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

David Carberry Biography and Net Worth

Director of Tyme Technologies

David Carberry has served as a member of our board of directors since 2017. Mr. Carberry has over 40 years of experience in the healthcare industry as a financial executive. From 2012 to 2016, Mr. Carberry was the Chief Financial Officer of Excellis Health Solutions, LLC, a consulting and software solutions company focused on the healthcare industry. From 2008 to 2010, Mr. Carberry was Chief Financial Officer of Aldagen, a biopharmaceutical company. From 1981 to 2008, Mr. Carberry served in a number of financial oversight roles within Johnson & Johnson, including Vice President, Finance of Independence Technology L.L.C., Johnson & Johnson/Merck Consumer Pharmaceuticals, and Vice President, Finance of Johnson Health Care Systems, Inc., a healthcare account management and business services provider. Mr. Carberry received a Bachelor of Science degree in Accounting from La Salle University and Master in Business Administration in Finance from Drexel University. Mr. Carberry is a Certified Management Accountant.

What is David Carberry's net worth?: The estimated net worth of David Carberry is at least $15,535.00 as of March 18th, 2020. Mr. Carberry owns 50,000 shares of Tyme Technologies stock worth more than $15,535 as of April 20th. This net worth approximation does not reflect any other assets that Mr. Carberry may own. Learn More about David Carberry's net worth.
How do I contact David Carberry?: The corporate mailing address for Mr. Carberry and other Tyme Technologies executives is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. Tyme Technologies can also be reached via phone at (212) 461-2315 and via email at [email protected]. Learn More on David Carberry's contact information.
Has David Carberry been buying or selling shares of Tyme Technologies?: David Carberry has not been actively trading shares of Tyme Technologies over the course of the past ninety days. Most recently, on Wednesday, September 22nd, David Carberry bought 50,000 shares of Tyme Technologies stock. The stock was acquired at an average cost of $1.03 per share, with a total value of $51,500.00. Learn More on David Carberry's trading history.
Who are Tyme Technologies' active insiders?: Tyme Technologies' insider roster includes James Biehl (Insider), David Carberry (Director), Michael Demurjian (Major Shareholder), Barbara Galaini (Insider), Steve Hoffman (Insider), and Jan Van Rornout (Insider). Learn More on Tyme Technologies' active insiders.

David Carberry Insider Trading History at Tyme Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/22/2021	Buy	50,000	$1.03	$51,500.00
3/18/2020	Buy	20,000	$0.95	$19,000.00	50,000
6/14/2019	Buy	30,000	$1.07	$32,100.00

David Carberry Buying and Selling Activity at Tyme Technologies

Tyme Technologies Company Overview

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.

Today's Range

Now: $0.31

$0.29

$0.32

50 Day Range

MA: $0.30

$0.24

$0.35

2 Week Range

Now: $0.31

$0.22

$1.14

Volume

2,678,186 shs

Average Volume

1,009,732 shs

Market Capitalization

$53.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93